aTyr Pharma | LIFE - Cash And Equivalent


aTyr Pharma reported $6.15M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Ardelyx USD 42.72M 47.32M Sep/2025
aTyr Pharma USD 6.15M 11.07M Sep/2025
Biogen USD 3.86B 1.1B Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Cipla INR 7.96B 39.9M Sep/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 7.46M 985K Sep/2025
CSL USD 2.16B 633M Jun/2025
Galapagos EUR 64.46M 43.61M Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Grifols EUR 979.78M 334.84M Dec/2024
Novartis USD 9.56B 2.9B Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
United Therapeutics USD 1.34B 253M Sep/2025